Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Medison Pharma Alnylam Pharmaceuticals United Kingdom Germany Spain New Zealand South Korea Switzerland Latin America Israel United States of America New York

The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global allianceMedison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of Alnylam's innovative RNAi technologies 

View original content:https://www.prnewswire.co.uk/news-releases/medison-pharma-and-alnylam-pharmaceuticals-announce-expansion-of-their-multi-regional-partnership-in-europe-and-israel-to-commercialize-rnai-therapeutics-in-additional-latam-and-apac-markets-including-australia-302131429.html